Comparison of iron chelators used alone or in combination with phlebotomy in common mynahs (Acridotheres tristis) with experimental iron storage disease

2021 ◽  
pp. 1-28
Author(s):  
Niloofar Jalili ◽  
Mahdieh Zaeemi ◽  
Jamshid Razmyar ◽  
Mohammad Azizzadeh
2012 ◽  
Vol 43 (3s) ◽  
pp. S27-S34 ◽  
Author(s):  
Kirk C. Klasing ◽  
Ellen S. Dierenfeld ◽  
Elizabeth A. Koutsos

Blood ◽  
2004 ◽  
Vol 103 (12) ◽  
pp. 4669-4671 ◽  
Author(s):  
Pauline L. Lee ◽  
Ernest Beutler ◽  
Sreenivas V. Rao ◽  
James C. Barton

AbstractJuvenile hemochromatosis is an early-onset form of iron storage disease characterized by hypogonadotrophic hypogonadism and cardiomyopathy. Recently, the putative causative gene (LOC148738) encoding a protein designated hemojuvelin was cloned. The previously proposed designation of this gene as HFE2 is contrary to established convention, because it is not a member of the HFE family. We suggest that it be designated HJV. We sequenced this gene in members of 2 previously reported kinships that manifest typical juvenile hemochromatosis. In one kinship, 2 previously undescribed mutations of HJV were identified, c.238T>C (C80R) and c.302T>C (L101P). In the second kinship, 2 previously identified mutations, G320V and I222N, were found. These studies confirm that mutations in HJV cause juvenile hemochromatosis. (Blood. 2004;103:4669-4671)


2002 ◽  
Vol 40 (6) ◽  
pp. 479-481
Author(s):  
K W Ocran ◽  
H H.-J Schmidt
Keyword(s):  

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3732-3732 ◽  
Author(s):  
Mohsen Saleh Elalfy ◽  
Iman Abdin

Abstract The liver is the main body site for iron storage. Iron chelators as DFo and L1 had problems of compliance and intolerance respectively. This prospective study enrolled 76 BTM patients aged from 9–33 years, mean of 14±4.4 to evaluate the effectiveness of both chelators judged by serum ferritin (sf) and liver iron content (LIC) using repeated liver biopsies. Fifty patients were on DFo 35 mg/kg/day 5 days per week and twenty-six were on L1 75 mg/kg/day on daily bases. Mean baseline sf values were 3678±1922 and 3573±1879 ng/ml while mean baseline LIC was 19.2±7.9 and 18.9±8.1 mg fe/g dw, while 12% and 14% showed evidence of liver fibrosis (score ≥ 3) respectively. Twenty-four months later; a decline in sf by 287±837 in Dfo (In Dfo compliant group [number = 30]who had received ≥ 75% of planned dose; sf dropped by 890±437 while increased in DFo non compliant by 621±513). While falling by 729±633 in L1 group. A decrease in LIC by 3.9±2.8 mg fe/g dw (−5.8±3.1 in Dfo compliant,+2.6±3.3 in Dfo non compliant) and falling by 2.2±3.4 mg fe/g dw in L1 group, the difference was statistically significant P< 0.05 between compliant and non compliant DFo and insignificant difference between Dfo and L1.The mean iron excretion: intake was 1.61,0.86 and 1.48 in Dfo compliant, non compliant and L1 respectively. A positive correlation was found between sf and LIC in both groups. Fibrosis was improved in Dfo compliant group better than L1 but no statistically significant difference was observed, while progressive fibrosis in 10% of Dfo non compliant group. All Dfo compliant group completed study, 18 out of 20 Dfo non compliant while six L1 patients discontinued the drug prematurely (3 severe gastrointestinal disturbances, 2 severe arthralgia and one repeated neutropenia). Conclusion: Both Dfo and L1 are effective iron chelators evident by drop in sf, LIC and improved fibrosis, however compliance and intolerance are still troublesome.


2011 ◽  
Vol 145 (2-3) ◽  
pp. 207-213 ◽  
Author(s):  
P. Olias ◽  
A.Th.A. Weiss ◽  
A.D. Gruber ◽  
R. Klopfleisch

Sign in / Sign up

Export Citation Format

Share Document